Scarica l'app Stockscreener
19.38
0.77%
-0.20
Precedente Chiudi:
$19.58
Aprire:
$19.57
Volume 24 ore:
107.18K
Relative Volume:
0.11
Capitalizzazione di mercato:
$637.56M
Reddito:
$17.16M
Utile/perdita netta:
$-163.62M
Rapporto P/E:
-3.1875
EPS:
-6.08
Flusso di cassa netto:
$-121.61M
1 W Prestazione:
-8.31%
1M Prestazione:
+14.97%
6M Prestazione:
-8.82%
1 anno Prestazione:
-25.92%
Intervallo 1D:
$19.09
$20.04
Intervallo di 1 settimana:
$18.51
$21.52
Portata 52W:
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Confronta ANAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
19.43 | 637.56M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.66 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.88 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
559.27 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.72 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
232.10 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
Susquehanna Fundamental Investments LLC Invests $593,000 in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Invesco Ltd. - MarketBeat
Barclays PLC Buys 39,267 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $54.00 at Guggenheim - MarketBeat
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Analysts Are Upgrading AnaptysBio, Inc. (NASDAQ:ANAB) After Its Latest Results - Yahoo Finance
AnaptysBio (NASDAQ:ANAB) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly? - simplywall.st
AnaptysBio First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Boxer Capital Management LLC Purchases New Shares in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Nebula Research & Development LLC Makes New $231,000 Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (ANAB) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
AnaptysBio Inc (ANAB) Q1 2025 Earnings: Revenue Surges to $27.8M - GuruFocus
AnaptysBio Inc (ANAB) Q1 2025 Earnings: Revenue Surges to $27.8M, Beating Estimates; EPS at -$1.28, Slightly Below Expectations - GuruFocus
Forecasting The Future: 6 Analyst Projections For AnaptysBio - Benzinga
AnaptysBio (ANAB) Price Target Raised by Guggenheim | ANAB Stock News - GuruFocus
AnaptysBio (ANAB) Price Target Increased Amid Promising Clinical Developments | ANAB Stock News - GuruFocus
AnaptysBio, Inc. (ANAB) Tops Q1 EPS by 2c - StreetInsider
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
AnaptysBio (ANAB) Surpasses Revenue Expectations with Strong Q1 Performance | ANAB Stock News - GuruFocus
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update | ANAB Stock News - GuruFocus
ANAPTYSBIO, INC SEC 10-Q Report - TradingView
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
BRIEF-AnaptysBio Q1 Net Income USD -39.329 Million - TradingView
Anaptys Breakthrough: Rosnilimab Shows Strong Phase 2b Results in RA, Multiple Pipeline Catalysts Ahead - Stock Titan
First Light Asset Management LLC Has $11.50 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Wedbush Reaffirms “Outperform” Rating for AnaptysBio (NASDAQ:ANAB) - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Geode Capital Management LLC - MarketBeat
JPMorgan Chase & Co. Has $1.52 Million Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Gears Up For Key Trial Readouts In Rheumatoid Arthritis And Lung Cancer - RTTNews
AnaptysBio (ANAB) Stock Maintains Outperform Rating with $40 Pri - GuruFocus
AnaptysBio (ANAB) Stock Maintains Outperform Rating with $40 Price Target | ANAB Stock News - GuruFocus
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
What is the investor’s view on AnaptysBio Inc (ANAB)? - uspostnews.com
A company insider recently bought 65,184 shares of AnaptysBio Inc [ANAB]. Should You Buy? - knoxdaily.com
AnaptysBio (NASDAQ:ANAB) versus Endonovo Therapeutics (OTCMKTS:ENDVD) Head-To-Head Comparison - Defense World
(ANAB) Investment Analysis and Advice - news.stocktradersdaily.com
Investor’s Delight: AnaptysBio Inc (ANAB) Closes Weak at 18.59, Down -1.90 - DWinneX
Gaining Ground: AnaptysBio Inc (ANAB) Closes Lower at 16.34, Down -0.37 - DWinneX
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Russell Investments Group Ltd. - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Geode Capital Management LLC - Defense World
JPMorgan Chase & Co. Raises Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
XTX Topco Ltd Buys 19,727 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Inc (ANAB) Stock: A Comprehensive 52-Week Review - investchronicle.com
What was AnaptysBio Inc (ANAB)’s performance in the last session? - uspostnews.com
Gaining Ground: AnaptysBio Inc (ANAB) Closes Lower at 20.42, Down -5.38 - DWinneX
ANAB Stock Sees Surge of Approximately 12.82% in Last Five Days - knoxdaily.com
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Federated Hermes Inc. - MarketBeat
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anaptysbio Inc Azioni (ANAB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
Dec 30 '24 |
Buy |
12.92 |
65,184 |
842,060 |
7,860,180 |
| EcoR1 Capital, LLC | Director |
Dec 31 '24 |
Buy |
12.93 |
13,268 |
171,513 |
7,873,448 |
| EcoR1 Capital, LLC | Director |
Jan 02 '25 |
Buy |
12.95 |
6,646 |
86,070 |
7,880,094 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Option Exercise |
6.93 |
10,000 |
69,300 |
11,950 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Sale |
25.00 |
10,000 |
250,000 |
1,950 |
5.73%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):